The past three decades has seen a major transformation in the understanding and management of HIV infection. Effec- Why is curing HIV so difficult?
HIV replicates at high levels in activated CD4 + T-cells. In the absence of treatment, there is a slow and gradual loss of CD4 + T-cells from blood and tissue and associated immune dysfunction. cART effectively stops active virus replication and within just weeks of starting treatment, there is a rapid decline in HIV RNA in blood to undetectable levels (<20 copies/ml). However, in nearly all patients, HIV RNA rebounds rapidly when treatment is stopped, usually within 2-3 weeks 4 . HIV can persist in patients on suppressive ART as a result of long lived latently infected cells, low level virus replication in some patients and anatomical reservoirs. Definitions of each of these terms are shown in Table 1 (adapted from Eisele and Siliciano  3 ) .
HIV latency and factors that regulate virus expression
HIV, similar to other retroviruses is able to establish latent infection in resting CD4 + T-cells 5, 6 . Latency occurs when HIV enters a cell and integrates into the host cellular DNA but there is absence of virus production. However, when given the appropriate stimuli, infectious virus can re-emerge [7] [8] [9] [10] . Latency primarily occurs in long-lived central memory and transitional memory T-cells and less frequently in naïve T-cells 6, 11 and cells of other lineages including monocytes, macrophages 12, 13 and astrocytes [14] [15] [16] . Latently infected cells can also be maintained through homeostatic proliferation 11 and recently, latency has also been demonstrated in memory stem cells which although infrequent, have the capacity to undergo self-renewal and expand over time on ART 17 . Latently infected resting CD4 + T-cells in patients on cART are estimated to occur at a frequency of 60 per million CD4 + T-cells 18 and there is likely to be some inter-patient variability. Unfortunately there are currently no phenotypic markers of a latently infected cell in vivo and this is a top priority for research currently.
Latent HIV infection in CD4 + T-cells is established early in HIV
infection and is seen even in patients who commenced cART within the first week of HIV infection 19, 20 . Latency can be established in CD4 + T-cells via two pathways: first, when the virus infects an activated CD4 + T-cell and the infected cell survives and reverts to a resting memory T-cell carrying an integrated provirus 3, 9, 21 . This is referred to as post-activation latency 22 . Second, via direct infection of resting CD4 + T-cells, which in vitro requires additional stimuli such as chemokines 23 , dendritic cell (DC) contact 24 or a high level of infecting virus and spinoculation 25 , termed pre-activation latency 22 . The relative contribution of pre-and post-activation latency in vivo is unknown.
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Once the virus integrates into the host genome, latency is maintained via multiple molecular mechanisms 9, 22 . These include tran- 
Residual virus replication
Whether there is residual virus replication (i.e. new rounds of HIV infection) in patients on cART remains controversial. Traditional methods of measuring sequence evolution over time suggest there is minimal change in plasma virus or cell-associated HIV DNA in patients on suppressive cART arguing that there is minimal virus replication 27 . In addition, development of drug resistance is not observed in patients on cART arguing against any replication 28 .
However, recent evidence suggest that drug penetration in tissue sites such as the gastrointestinal tract and lymphoid tissue is suboptimal in patients on cART which could potentially favour some residual replication in these tissue sites 29 . Two randomised studies of patients on suppressive cART who intensified their cART regimen with the addition of an integrase inhibitor, raltegravir demonstrated that residual replication occurred in roughly 30% of patients 30, 31 . The persistent detection of low level viraemia at 1-3 copies/mL in nearly all patients on cART 32 may represent either release of virus from long-lived latently infected cells or residual virus replication.
The former is more likely given the relative homogeneity of genetic sequences seen in low-level viraemia over time 33 .
Anatomical reservoirs
HIV can also persist in distinct anatomical sites -due to long-lived 
Is a cure possible?
Over the last few years, several cases of HIV cure have been reported.
The only case of a sterilising cure is Timothy Brown, also known as the 'Berlin patient' 38 . Timothy Brown received two allogeneic stem cell transplants for acute myeloid leukaemia from a donor with a homozygous CCR5 delta32 deletion 38 . CCR5 is a co-receptor for HIV and is required for HIV to enter a cell. In the absence of CCR5, a T-cell is resistant to infection with CCR5-using strains of HIV [39] [40] [41] .
Remarkably, Mr Brown remains cured of HIV six years after cessation of cART with no detectable infectious virus in blood or tissue 38, 42, 43 .
The other cases of HIV cure are all cases of functional cure -or longterm control in the absence of cART. These occur largely in the setting of early cART treatment -perhaps early enough to limit the number of latently infected cells and or to preserve an adequate HIV-specific T-cell response 20, 44 . Indeed, a group of 14 post-treat- Current research strategies towards a cure In comparison, viral rebound is still expected in 3 and 10 years, respectively, if 100 or 10 infected cells remain 54 .
Clearly the toxicity, safety and ethics of HSCTs preclude this as a practical HIV cure for all. Further, finding a CCR5 delta32 deletion donor is extremely difficult as this is exceedingly rare globally 55 .
Stem cell donor registries do not currently routinely test for CCR5 status 56 . A database of CCR5 delta32 negative cord blood exists and dual transplantation (cord blood and HSCT) is being considered 56, 57 .
Gene therapy
A variety of stem-cell based gene therapy are being exploredtargeting cellular genes necessary for viral replication (such as CCR5 co-receptor), directly against HIV gene expression (such as tat and rev protein) and those that introduce genes to interfere with HIV replication (such as host restriction factors or fusion inhibitors) 58 .
Zinc finger proteins are sequence-specific DNA binding proteins that can be coupled to a DNA endonuclease (zinc finger nuclease (ZFN)) to cut DNA at specific sites 58 . CCR5 ZFNs aims to eliminate CCR5 expression thus gene-modifying the cell to be resistant to HIV. This is currently performed using an adenovirus delivery vector to T-cells ex vivo and future studies will use a similar approach for stem cells 51 . This approach was shown to be safe in a recent study of 12 patients who received CCR5-modified cells 59 . Indeed, CCR5-modified CD4 + T-cells peaked one week after engraftment and constituted a median frequency of 8.8% of peripheral blood mononuclear cells and 13.9% of total circulating CD4 + T-cells 59 . The modified cells declined but persisted for up to 48-weeks and were also detectable in the rectal mucosa 59 . Even though HIV viral load rebounded following cART treatment interruption, the decline in CCR5-modified CD4 + T-cells was less than in the unmodified CD4 + T-cell population suggesting some survival advantage 59 .
The other approach is to target the virus itself. A lentiviral vector to introduce a gene encoding a short hairpin RNA (sh5) against CCR5 is being combined with a HIV fusion inhibitor (C46) 56 . This LVsh5/C46
vector is being trialled as a Phase I/II clinical trial (CAL-USA-11, NCT01734850) in HIV-infected patients 51 . 
Activating latent HIV
Activating transcription from latently infected cells is being investigated as part of a 'kick and kill' strategy, which aims to induce production of virus from latency (the kick), thus making the recently activated latently infected cell susceptible to virus-induced cytolysis or HIV-specific immunity (the kill) 64 . Some approaches include histone deacetylase inhibitors (HDACi), disulfiram, methylation inhibitors, cytokines and immune modulators (reviewed in Wightman et al. 65 ).
Histone deacetylase inhibitors (HDACi)
Histone acetyltransferase leads to a hyperacetylated euchromatin state which is a transcriptionally-active, open state while histone
In Focus Recently, a more potent pan-HDACi, panobinostat was adminis- 
Disulfiram
Disulfiram is a member of the dithiocarbamate family, a broad class of metal-chelators, used previously to deter alcohol abuse 75 . Disulfiram activated viral production from latent HIV in vitro, in some but not all laboratory models of latency 76 and it was recently demonstrated that activation was secondary to modification of the PTEN (phosphatase and tensin homologue) pathway 77 . An open label study of daily disulfiram given for 14 days recorded a transient rise in HIV RNA in a subset of patients with high disulfiram levels without a reduction in the number of latently-infected cells 78 . A dose-escalation study is currently ongoing (NCT01944371) 51 .
IL-7
IL-7 has recently been investigated as an agent that could enhance T-cell proliferation 79 and potentially activate HIV transcription from latency, but recent studies suggested that IL-7 causes proliferation of both infected and uninfected cells and an expansion of the HIV reservoir 80 and an increase in HIV DNA (Eramune 01, NCT01019551) 51 . Enhancing HIV-specific immunity
Reducing virus replication and/or immune activation

Therapeutic vaccination
It is likely that boosting immunity will be required in combination . A study on interferon-alpha-2b intensification is ongoing (NCT01295515) 51 .
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Challenges to HIV cure research
There are considerable challenges ahead. Development of new drugs will depend on having a biomarker that can predict long term virological control following cessation of cART. Better in vitro models are needed to effectively screen compounds that activate latent infection [87] [88] [89] . We need more accurate and reproducible assays to quantify virus in both blood and tissue. Involvement of the private sector to date has been limited largely due to the absence of good biomarkers, in vitro and animal models of HIV latency.
Novel strategies or collaborative programs are needed that can enhance engagement of private industry. Involving people living with HIV will be essential in all aspects of study design and implementation. Lastly, HIV cure strategies must be equitable and accessible to all including those in resource-limited settings -accordingly, clinical HIV cure trials in these settings should be urgently pursued.
Conclusion
Despite the recent excitement related to reports that an HIV cure is possible and the increasing scientific interest in finding a cure, a cure is many years away. Finding a cure for HIV will require innovation, collaboration and significant funding. The task is too great for any single laboratory or country. A number of collaborative initiatives focusing on cure are now established. The lessons learnt, and hopefully successes gained from these consortia are eagerly awaited.
